• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

    6.820 -0.650 (-8.70%)
    Streaming Delayed Price Updated: 2:59 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 126,738
    Open 7.480
    Bid (Size) 6.780 (1)
    Ask (Size) 6.880 (6)
    Prev. Close 7.470
    Today's Range 6.750 - 7.616
    52wk Range 5.850 - 12.10
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
    The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
    Via News Direct
    PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
    From PESG Research
    Via Business Wire

    Performance

    YTD
    -17.73%
    -17.73%
    1 Month
    +7.06%
    +7.06%
    3 Month
    +10.36%
    +10.36%
    6 Month
    +0.89%
    +0.89%
    1 Year
    -25.79%
    -25.79%

    More News

    Read More
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
    Via News Direct
    Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
    Via News Direct
    PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
    From PESG Research
    Via Business Wire
    Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
    Via News Direct
    Exposures Product Safety
    Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
    Via AB Newswire
    Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
    Via AB Newswire
    Precision Medicine M&A is Transforming the Future of the Biotech Industry
    Via AB Newswire
    7 Penny Biotech Stocks to Triple Your Investment
    Via InvestorPlace
    Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    5 Healthcare Stocks to Buy for 2024
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma to Present at the 36th Annual Roth Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.